This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| F |
FORMULATIONS |
| F1A1 |
FORMULATION, INHALABLE, DRY POWDER
Dry powder formulations delivered by inhalation. |
| F1A2 |
FORMULATION, INHALABLE, SOLUTION
Aqueous formulations delivered by inhalation. |
| F1B1 |
FORMULATION, INHALABLE, SYSTEMIC
Inhaled formulations for the treatment of non-pulmonary disorders. |
| F1B2 |
FORMULATION, INHALABLE, TOPICAL
Inhaled formulations for the treatment of pulmonary disorders. |
| F1Z9 |
FORMULATION, INHALABLE, OTHER
All products that cannot be placed in any of the inhalable formulation categories (F1A-F1B2). |
| F2A1 |
FORMULATION, MODIFIED-RELEASE, <=24HR
Extended release formulations that exert their effects over a time period less than or equal to 24hr. |
| F2A2 |
FORMULATION, MODIFIED-RELEASE, >24HR
Extended release formulations that exert their effects over a time period greater than 24hr. |
| F2B |
FORMULATION, MODIFIED-RELEASE, MULTI
Tablets or capsules which contain 2 or more layers of a drug (or drugs) which degrade at different rates, resulting in a multiple dosing schedule through a single administration. |
| F2C |
FORMULATION, MODIFIED-RELEASE, IMMEDIATE
Formulations of drugs that are active immediately upon administration. The formulations are administered by a method which is unconventional compared to traditional route of administration. |
| F2Z9 |
FORMULATION, MODIFIED-RELEASE, OTHER
All modified release formulations that cannot be placed in any of the other modified release formulation categories (F2A1-F2C). |
| F3A1 |
FORMULATION, OPTIMIZED, MICROPARTICLES
Formulations where drug particles are fabricated with dimensions greater than or equal to 100 nanometres. |
| F3A2 |
FORMULATION, OPTIMIZED, NANOPARTICLES
Formulations where drug particles are fabricated with dimensions of less than 100 nanometres. |
| F3C1 |
FORMULATION, OPTIMIZED, MICROENCAPSULATE
Drugs that are packaged (as solids or liquids) in the form of capsules. The capsule wall material can be formulated by using a variety of materials, including natural and synthetic molecules. Includes microcapsules, microcells, microspheres. Does not include liposomes. For liposomes see F3C9. |
| F3C2 |
FORMULATION, OPTIMIZED, LIPOSOMES
A type of microencapsulation technique, where the walls of the capsule are made of layers of phospholipids, the major component of cell membranes. |
| F3D |
FORMULATION, OPTIMIZED, DRUG-LOADED
Where the drug is adsorbed to the outside of a particle (as opposed to being contained within a structure as with microencapsulation). |
| F3E |
FORMULATION, OPTIMIZED, MICROEMULSION
A microemulsion is a thermodynamically-stable dispersion of one liquid phase into another, stabilized by an interfacial film of surfactant. This dispersion may be either oil-in-water or water-in-oil. Microemulsions are typically clear solutions, as the droplet diameter is approximately 100 nanometers or less. |
| F4A |
FORMULATION, ORAL, SOLUBILITY-ENHANCED
Drugs formulated in vehicles/excipients that improve the solubility of the product. |
| F4B |
FORMULATION, ORAL, ENTERIC COATED
Products in the form of a capsule or tablet that are covered with a special coating so that the release of their contents is delayed until they reach the intestines. |
| F4C |
FORMULATION, ORAL, TARGETED
Products that exert their effects or become activated at a specific location in the body. Does not include enteric coated products (see F4B). |
| F4D |
FORMULATION, ORAL, ORALLY-DISINTEGRATING
Products which dissolve within seconds when placed in mouth. |
| F4Z9 |
FORMULATION, ORAL, OTHER
All oral formulations that cannot be placed in any of the other oral formulation categories (F4A-F4C). |
| F5A |
FORMULATION, PARENTERAL, NEEDLE-FREE
Products formulated as dry powders or liquidsthat are propelled through the skin via a needle-free injection device. |
| F5B |
FORMULATION, PARENTERAL, TARGETED
Parenteral products that use a targeting system to localize the active drug to a specific location in the body. |
| F5Z9 |
FORMULATION, PARENTERAL, OTHER
All parenteral formulations that cannot be placed in any of the parenteral formulation categories (F5A1-F5B). |
| F6A1 |
FORMULATION, DERMAL, TOPICAL
Formulations that are applied to the skin for the treatment of demal/dermatological conditions. |
| F6A2 |
FORMULATION, TRANSDERMAL, SYSTEMIC
Formulations that are applied to the skin for transdermal delivery to other organs. |
| F6B |
FORMULATION, TRANSDERMAL, PATCH
Products integrated into patches to pass across the dermal layer. |
| F6C |
FORMULATION, TRANSDERMAL, ENHANCED
Products integrated into transdermal vehicles or delivered by heat- or electricity-assisted systems for enhanced dermal penetration. |
| F6Z9 |
FORMULATION, TRANSDERMAL, OTHER
All transdermal formulations that cannot be placed in any of the transdermal formulation categories (F6A1-F6C). |
| F7Z |
FORMULATION, TECHNOLOGY
Novel formulation systems and delivery devices. |
| F8A1 |
FORMULATION, MUCOSAL, TOPICAL
Formulations that are applied to mucosal membranes for the treatment of local conditions. |
| F8A2 |
FORMULATION, TRANSMUCOSAL, SYSTEMIC
Formulations that are applied to mucosal membranes for transmucosal delivery to other organs. |
| F8B |
FORMULATION, TRANSMUCOSAL, NASAL
Formulations that are absorbed through the nasal mucosa for the treatment of systemic or topical conditions. |
| F9A |
FORMULATION, IMPLANT
Depot formulations of active ingredient where there is a need to limit high drug concentration to the immediate area surrounding the pathology or to provide sustained drug release for systemic therapy. |
| F9B |
FORMULATION, FIXED-DOSE COMBINATION
Formulations using standard drug combinations. |
| F9C1 |
FORMULATION, CONJUGATE, PEGYLATED
Pegylation is a process whereby a substance called polyethylene glycol (PEG) is attached to a protein in order to extend its activity. |
| F9C2 |
FORMULATION, CONJUGATE, CARBOHYDRATE
Carbohydrate conjugation is a process whereby a carbohydrate moiety is attached to a drug in order to extend its duration of activity or to allow carbohydrate-specific targeting. |
| F9Z9 |
FORMULATION, OTHER
All formulations that cannot be placed in any of the other formulation categories (F1A1-F9C2). |
Dialog1
Support Home
View the PDF version of this document